Renaissance Capital logo

OPH.RC News

Out of sight: Israeli ophthalmics biotech OphthaliX withdraws 2013 US IPO due to merger

OphthaliX, a clinical-stage biotech developing treatments for ophthalmic disorders, withdrew its plans for an initial public offering on Tuesday. It originally filed in July 2013 with a proposed deal size of $10 million. The Petach Tikva, Israel-based company was founded in 1999 and had planned to list on the NYSE. Maxim Group LLC was set to be the sole bookrunner on the deal....read more

US IPO Recap: Quiet week for pricings, but active IPO pipeline foreshadows busy July and August

The US IPO market slowed last week in the wake of June’s volatility and in anticipation of the Fourth of July holiday, with no deals pricing and only one deal setting terms. However, there are currently 118 deals in the pipeline, 21 of which submitted new or updated filings in the last 7 days. This heightened activity in the pipeline suggests that many deals could be ready...read more

Clinical-stage biotech OphthaliX files for a $10 million IPO

OphthaliX, a clinical-stage biotech developing treatments for ophthalmic disorders, filed on Tuesday with the SEC to raise up to $10 million in an initial public offering. The Petach Tikva, Israel-based company, which was founded in 1999, plans to list on the NYSE but has yet to announce a ticker. Maxim Group is the sole bookrunner on the deal. No pricing terms were disclosed....read more

Archived Headlines